Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IL-2

- PMLiVE

Tecentriq approved in Europe for triple negative breast cancer

Roche can dominate in niche setting

- PMLiVE

Celgene cuts back Jounce alliance ahead of BMS merger

Next-gen immuno-oncology alliance lives on

- PMLiVE

Building Europe’s next breakthrough biotechs

Start Codon's Daniel Rooke on fostering biotech success in Cambridge, UK

- PMLiVE

Novartis and J&J back latest €400m Medicxi biopharma fund

Growing appetite from European investors to back early-stage biotechs

- PMLiVE

Illumina sets up first ex-US accelerator site in Cambridge

Boost for UK's golden triangle biotech region

- PMLiVE

Gilead strikes $5.1bn deal to bolster ties with Galapagos

Big boost for Belgian biotech, without a buy-out

- PMLiVE

BioNTech raises €290m for mRNA cancer vaccine platform

Funds will help lead melanoma candidate progress

- PMLiVE

Citryll snares €15m backing for its autoimmune disease NETs

New approach to tackling diseases such as lupus, RA

- PMLiVE

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

Licensed to treat one of the most commonly diagnosed skin cancers

- PMLiVE

Scancell preps phase 2 challenge for melanoma vaccine

Progress continues for biotech

- PMLiVE

$450m diagnostics sale will fuel more Syncona biotech funding

Radiopharmaceuticals firm sold to Braco Imaging

- PMLiVE

Syncona start-up Quell Therapeutics appoints chief exec

Biotech focusing on Tregs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links